4-去甲基伊曲茶碱 | 160434-48-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 中文名称: 4-去甲基伊曲茶碱
• 中文别名: 4-去甲基异氟烷；伊曲茶碱杂质
• 英文名称: 4′-O-monodesmethyl istradefylline
• 英文别名: 4-Desmethyl Istradefylline；1,3-diethyl-8-[(E)-2-(4-hydroxy-3-methoxyphenyl)ethenyl]-7-methylpurine-2,6-dione
• CAS: 160434-48-0
• 化学式: C₁₉H₂₂N₄O₄
• 分子量: 370.408
• InChiKey: OHGCYFOMTIEDMR-CSKARUKUSA-N

物化性质

• 沸点：
  604.8±65.0 °C(Predicted)
• 密度：
  1.30±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  87.9
• 氢给体数：
  1
• 氢受体数：
  5

制备方法与用途

生物活性

4-Desmethyl Istradefylline 是istradefylline（I927000）的代谢物。Istradefylline 是一种有效的、选择性的、可口服的 adenosine A2A 受体拮抗剂，在帕金森病模型试验中，其 Ki 值为 2.2 nM。

用途

4-Desmethyl Istradefylline 是istradefylline的一种杂质，而istradefylline是一种用于治疗帕金森病的选择性 A(2A) 受体拮抗剂。研究表明，4-Desmethyl Istradefylline 具有抑制 adenosine A2A 受体的活性，并被分类为 adenosine A2A 受体拮抗剂。

反应信息

• 作为反应物：
  描述：

  4-去甲基伊曲茶碱 在 potassium carbonate 、 sodium hydroxide 作用下， 以 甲醇 、 丙酮 为溶剂， 反应 74.0h， 生成 (E)-4-(4-(2-(1,3-diethyl-7-methyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)vinyl)-2-methoxyphenoxy)butanoic acid
  参考文献：
  名称：

  Novel adenosine A2A receptor ligands: A synthetic, functional and computational investigation of selected literature adenosine A2A receptor antagonists for extending into extracellular space

  摘要：

  Growing evidence has suggested a role in targeting the adenosine A(2A) receptor for the treatment of Parkinson's disease. The literature compounds KW 6002 (2) and ZM 241385 (5) were used as a starting point from which a series of novel ligands targeting the adenosine A(2A) receptor were synthesized and tested in a recombinant human adenosine A(2A) receptor functional assay. In order to further explore these molecules, we investigated the biological effects of assorted linkers attached to different positions on selected adenosine A(2A) receptor antagonists, and assessed their potential binding modes using molecular docking studies. The results suggest that linking from the phenolic oxygen of selected adenosine A(2A) receptor antagonists is relatively well tolerated due to the extension towards extracellular space, and leads to the potential of attaching further functionality from this position. Crown Copyright (C) 2013 Published by Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.03.070
• 作为产物：
  描述：

  (E)-4-(3-((6-amino-1,3-diethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)amino)-3-oxoprop-1-en-1-yl)-2-methoxyphenyl acetate 在 硫酸氢铵 、 lithium aluminium tetrahydride 、 六甲基二硅烷 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 150.0 ℃ 、900.02 kPa 条件下， 反应 3.0h， 生成 4-去甲基伊曲茶碱
  参考文献：
  名称：

  Novel adenosine A2A receptor ligands: A synthetic, functional and computational investigation of selected literature adenosine A2A receptor antagonists for extending into extracellular space

  摘要：

  Growing evidence has suggested a role in targeting the adenosine A(2A) receptor for the treatment of Parkinson's disease. The literature compounds KW 6002 (2) and ZM 241385 (5) were used as a starting point from which a series of novel ligands targeting the adenosine A(2A) receptor were synthesized and tested in a recombinant human adenosine A(2A) receptor functional assay. In order to further explore these molecules, we investigated the biological effects of assorted linkers attached to different positions on selected adenosine A(2A) receptor antagonists, and assessed their potential binding modes using molecular docking studies. The results suggest that linking from the phenolic oxygen of selected adenosine A(2A) receptor antagonists is relatively well tolerated due to the extension towards extracellular space, and leads to the potential of attaching further functionality from this position. Crown Copyright (C) 2013 Published by Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.03.070

文献信息

• 8-substituted styryl xanthine derivatives
  申请人：Kyowa Hakko Kogyo Co., Ltd.

  公开号：US05670498A1

  公开（公告）日：1997-09-23

  Disclosed are xanthine derivatives represented by the following Formula (I): ##STR1## in which R.sup.1, R.sup.2, and R.sup.3 independently represent hydrogen or lower alkyl; Q.sup.1, Q.sup.2, and Q.sup.3 independently represent hydrogen, lower alkyl, lower alkoxy, or halogen; and X represents --COR.sup.4 (in which R.sup.4 represents hydrogen, hydroxy, lower alkyl, or lower alkoxy) or --SO.sub.2 R.sub.5 in which R.sup.5 represents hydroxy, lower alkoxy, trifluoromethyl, ##STR2## in which R.sup.6 and R.sup.7 independently represent hydrogen, hydroxy-substituted or unsubstituted lower alkyl, aryl, or ##STR3## (in which m represents an integer of 1 to 3; and R.sup.8 and R.sup.9 independently represent hydrogen or lower alkyl), or ##STR4## (in which Y represents a single bond, oxygen, or N--R.sup.10 in which R.sup.10 represents hydrogen or lower alkyl; and n1 and n2 independently represent an integer of 1 to 3)}, and pharmaceutically acceptable salts thereof.

  揭示了由以下式（I）表示的黄嘌呤衍生物：其中R.sup.1、R.sup.2和R.sup.3独立地代表氢或较低的烷基；Q.sup.1、Q.sup.2和Q.sup.3独立地代表氢、较低的烷基、较低的烷氧基或卤素；X代表--COR.sup.4（其中R.sup.4代表氢、羟基、较低的烷基或较低的烷氧基）或--SO.sub.2R.sub.5 其中R.sup.5代表羟基、较低的烷氧基、三氟甲基，##STR2##其中R.sup.6和R.sup.7独立地代表氢、羟基取代或未取代的较低烷基、芳基，或##STR3##（其中m表示1到3的整数；R.sup.8和R.sup.9独立地代表氢或较低的烷基），或##STR4##（其中Y代表单键、氧或N--R.sup.10，其中R.sup.10代表氢或较低的烷基；n1和n2独立地表示1到3的整数）以及其药学上可接受的盐。
• 伊曲茶碱去甲基杂质的制备方法
  申请人：南京安杰新生物医药有限公司

  公开号：CN113248505A

  公开（公告）日：2021-08-13

  本发明属于药物化学技术领域，具体涉及一种伊曲茶碱去甲基杂质的制备及纯化方法。以伊曲茶碱为原料，制备高纯度的三种去甲基杂质化合物：I、II和III，该方法工艺简单、易操作、纯化简单、收率高，所制备的杂质纯度高，能够为伊曲茶碱的质量控制提供合格的杂质对照品。本发明公开制备的伊曲茶碱杂质对照品可为伊曲茶碱工艺研发中该杂质的监控提供重要参照依据，提高伊曲茶碱质量监控水平，对于药用伊曲茶碱的开发具有重大的意义与实用价值。
• Xanthine derivatives
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP0607607A1

  公开（公告）日：1994-07-27

  Disclosed are xanthine derivatives represented by the following Formula (I): in which R¹, R², and R³ independently represent hydrogen or lower alkyl; Q¹, Q², and Q³ independently represent hydrogen, lower alkyl, lower alkoxy, or halogen; and X represents -COR⁴ (in which R⁴ represents hydrogen, hydroxy, lower alkyl, or lower alkoxy) or -SO₂R⁵ in which R⁵ represents hydroxy, lower alkoxy, trifluoromethyl, in which R⁶ and R⁷ independently represent hydrogen, hydroxy-substituted or unsubstituted lower alkyl, aryl, or (in which m represents an integer of 1 to 3; and R⁸ and R⁹ independently represent hydrogen or lower alkyl), or (in which Y represents a single bond, oxygen, or N-R¹⁰ in which R¹⁰ represents hydrogen or lower alkyl; and n1 and n2 independently represent an integer of 1 to 3 )}, and pharmaceutically acceptable salts thereof.

  所公开的是由下式 (I) 所代表的黄嘌呤衍生物： 其中 R¹、R² 和 R³ 独立地代表氢或低级烷基； Q¹、Q² 和 Q³ 独立地代表氢、低级烷基、低级烷氧基或卤素； X代表-COR⁴（其中R⁴代表氢、羟基、低级烷基或低级烷氧基）或-SO₂R⁵ 其中R⁵代表羟基、低级烷氧基、三氟甲基、 其中 R⁶ 和 R⁷ 独立地代表氢、羟基取代或未取代的低级烷基、芳基，或 (其中 m 代表 1 至 3 的整数；R⁸ 和 R⁹ 独立地代表氢或低级烷基），或 (其中 Y 代表单键、氧或 N-R¹⁰，其中 R¹⁰ 代表氢或低级烷基；且 n1 和 n2 独立地代表 1 至 3 的整数）}，及其药学上可接受的盐。
• XANTHINE DERIVATIVE
  申请人：KYOWA HAKKO KOGYO KABUSHIKI KAISHA

  公开号：EP0698607A1

  公开（公告）日：1996-02-28

  A xanthine derivative represented by general formula (I) or a pharmacologically acceptable salt thereof, wherein R¹, R² and R³ are the same or different from one another and each represents hydrogen, lower alkyl, lower alkenyl or lower alkynyl; R⁴ represents lower alkyl or (un)substituted aryl; R⁵ and R⁶ are the same or different from each other and each represents hydrogen, lower alkyl or lower alkoxy, or R⁵ and R⁶ are combined together to represent -O-(CH₂)p-O- (wherein p represents an integer of 1 to 3); n represents 0, 1 or 2; and m represents 1 or 2. The compound has an adenosine A₂ receptor antagonism and is useful for treating or preventing various diseases caused by the hyperfunctioning of adenosine A₂ receptors, such as Parkinson's disease, senile dementia, depression, asthma or osteoporosis.

  通式(I)代表的黄嘌呤衍生物或其药理学上可接受的盐，其中 R¹、R² 和 R³ 彼此相同或不同，各自代表氢、低级烷基、低级烯基或低级炔基；R⁴ 代表低级烷基或(未)取代的芳基；R⁵ 和 R⁶ 彼此相同或不同，且各自代表氢、低级烷基或低级烷氧基，或 R⁵ 和 R⁶ 结合在一起代表 -O-(CH₂)p-O-（其中 p 代表 1 至 3 的整数）；n 代表 0、1 或 2；以及 m 代表 1 或 2。该化合物具有腺苷 A₂受体拮抗作用，可用于治疗或预防由腺苷 A₂受体功能亢进引起的各种疾病，如帕金森病、老年痴呆症、抑郁症、哮喘或骨质疏松症。
• Gillies; Luthra; Brady, Journal of labelled compounds and radiopharmaceuticals, 1999, vol. 42, # SUPPL. 1, p. S456-S458
  作者：Gillies、Luthra、Brady、Karasawa、Shimada、Kase、Brooks

  DOI：——

  日期：——